772 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More http://www.zacks.com/stock/news/588895/drug-biotech-stock-q3-earnings-due-on-oct-29-mrk-pfe-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-588895 Oct 28, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings? http://www.zacks.com/stock/news/584443/will-nuplazid-aid-growth-for-acadia-acad-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-584443 Oct 25, 2019 - During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings? http://www.zacks.com/stock/news/584435/can-cf-drugs-drive-growth-for-vertex-vrtx-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-584435 Oct 25, 2019 - During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
Can Merck (MRK) Keep the Earnings Beat Streak Alive in Q3? http://www.zacks.com/stock/news/582015/can-merck-mrk-keep-the-earnings-beat-streak-alive-in-q3?cid=CS-ZC-FT-analyst_blog|earnings_preview-582015 Oct 24, 2019 - Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven third-quarter sales. However, genericization of key drugs and increased competition are concerns.
Acorda (ACOR) to Post Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/582508/acorda-acor-to-post-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-582508 Oct 24, 2019 - During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates http://www.zacks.com/stock/news/578821/biotech-stock-roundup-biib-up-on-ad-data-alxn-to-buy-achn-other-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-578821 Oct 23, 2019 - Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
5 High-Flying Corporate Giants Set to Beat on Q3 Earnings http://www.zacks.com/stock/news/578628/5-high-flying-corporate-giants-set-to-beat-on-q3-earnings?cid=CS-ZC-FT-analyst_blog|investment_ideas-578628 Oct 23, 2019 - Despite almost day-to-day market fluctuations, a few corporate behemoths surged in Wall Street. Some of these are set to beat earnings estimate in the ongoing reporting cycle.
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store? http://www.zacks.com/stock/news/575664/exact-sciences-exas-to-post-q3-earnings-whats-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-575664 Oct 21, 2019 - During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
What's in Store for Healthcare ETFs in Q3 Earnings? http://www.zacks.com/stock/news/575582/whats-in-store-for-healthcare-etfs-in-q3-earnings?cid=CS-ZC-FT-etf_news_and_commentary-575582 Oct 21, 2019 - With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Alexion Gets FDA Approval for Label Expansion of Ultomiris http://www.zacks.com/stock/news/575533/alexion-gets-fda-approval-for-label-expansion-of-ultomiris?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-575533 Oct 21, 2019 - Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.

Pages: 123456789...78

<<<Page 4>